| Literature DB >> 24447850 |
Thierry Sifferlen1, Amandine Boller1, Audrey Chardonneau1, Emmanuelle Cottreel1, Johannes Hoecker1, Hamed Aissaoui1, Jodi T Williams1, Christine Brotschi1, Bibia Heidmann1, Romain Siegrist1, John Gatfield1, Alexander Treiber1, Catherine Brisbare-Roch1, Francois Jenck1, Christoph Boss2.
Abstract
Starting from a thiazolidin-4-one HTS hit, a novel series of substituted lactams was identified and developed as dual orexin receptor antagonists. In this Letter, we describe our initial efforts towards the improvement of potency and metabolic stability. These investigations delivered optimized lead compounds with CNS drug-like properties suitable for further optimization.Entities:
Keywords: CNS drug discovery; G-protein coupled receptors; Metabolic stability; Orexin antagonists; Structure–activity relationship studies
Mesh:
Substances:
Year: 2013 PMID: 24447850 DOI: 10.1016/j.bmcl.2013.12.092
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN: 0960-894X Impact factor: 2.823